Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →French drugmaker Sanofi agreed to pay $125 million to startup Earendil Labs for two drug candidates designed to treat autoimmune and inflammatory bowel…
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology. The deal sees Sanofi handing over $125 million upfront with a…
Jan 5, 2026: Earendil and Sanofi announced a SEPARATE, expanded strategic collaboration applying Earendil's AI discovery platform to multiple…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi obtained exclusive worldwide rights to two AI-engineered bispecific antibodies (HXN-1002 targeting α4β7/TL1A and HXN-1003 targeting TL1A/IL23) for autoimmune and IBD indications. Earendil received $125M upfront and is eligible for up to $1.72B in milestones plus tiered royalties. Follow-on validation: in January 2026 Sanofi and Earendil signed a separate, broader strategic collaboration (up to $160M upfront/near-term, up to $2.56B total) applying Earendil's AI discovery platform to additional autoimmune/inflammatory programs, reinforcing the platform thesis behind this initial HXN-1002/HXN-1003 license.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Earendil Labs, Inc. (this deal) | 2025 | $1.8B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2025 deals · Sanofi SA deals · Immunology deals